Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives $26.67 Average Target Price from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $26.6667.

NBTX has been the subject of several recent research reports. Guggenheim upped their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Finally, UBS Group lifted their price objective on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st.

Nanobiotix Price Performance

Shares of Nanobiotix stock opened at $41.01 on Tuesday. Nanobiotix has a 12 month low of $3.81 and a 12 month high of $57.14. The business has a fifty day simple moving average of $36.04 and a 200 day simple moving average of $27.87.

Nanobiotix (NASDAQ:NBTX) last posted its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. As a group, equities research analysts expect that Nanobiotix will post 0.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Nanobiotix

A number of large investors have recently modified their holdings of the business. Optiver Holding B.V. bought a new position in shares of Nanobiotix in the 3rd quarter valued at $101,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the 4th quarter worth about $220,000. Royal Bank of Canada raised its position in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Nanobiotix in the 4th quarter worth about $390,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.